« Previous article
World's Largest ...

22nd June 2021  Product update: rapidvirology staff writer

Fully-Automated CE-Marked CLIA High-Throughput Solution for Diagnosing Hepatitis E

DiaSorin has launched a new LIAISON® Murex Anti-HEV IgG & IgM assay for the diagnosis of Hepatitis E (HEV). This test is the first CLIA fully automated high-throughput solution for the diagnosis of HEV and is available in countries accepting the CE Mark for use on the LIAISON® family platforms. 

HEV infection is a major cause of acute hepatitis and it is increasingly spreading worldwide, with about 20 million new infections occurring annually. The diagnosis of HEV infection supports the clinical patient management and avoids the spread of the infection. HEV usually spreads to humans through the food chain via fecal contamination of drinking water or consumption of meat from infected animals, but iatrogenic transmission (i.e. caused by medical treatments) is also possible.

Infection with the virus causes Hepatitis E, which usually presents as an acute, self-limiting form of liver inflammation. However, acute hepatitis can progress to chronic hepatitis, cirrhosis, liver failure and acute-on-chronic liver failure. 

Over the past decade, interest in HEV infection has increased after the description of cases of chronic hepatitis in immunosuppressed individuals, reports of severe HEV-associated extrahepatic manifestations and the presence of HEV in blood products used for transfusion. 

The LIAISON® Hepatitis panel is now the world broadest and fully automated, CLIA solution for the diagnosis of viral hepatitis (including Hepatitis A, B, C, D, and E), and it speeds the time-to-treatment in individuals with or without hepatitis symptoms, and assist the monitoring of disease progression and treatment status. “The launch of this new test broadens our CLIA offering for the Hepatitis and Retroviruses diagnosis and shows, once again, our commitment to focus on innovative products, strengthening our specialist positioning in the diagnostic industry”, commented Carlo Rosa, CEO of DiaSorin.

For further details, please use the 'Request Information' button provided below. 



Date Published: 22nd June 2021

Source article link: View

Note: This content has been edited by a rapidvirology.com staff writer for style and content.

View full company details

Related news